| Name | Title | Contact Details |
|---|
With a history of over 25 years, Ceto has forged enduring partnerships with over 2,000 regional and community banks and credit unions nationwide, igniting their profitability and growth. Our unwavering commitment lies in empowering financial institutions with cutting-edge intelligence and transformative solutions, elevating shareholder value, and fostering thriving, prosperous communities. Discover more at ceto.com or dial 866.227.1361 to embark on a transformative journey.
HealthSherpas mission is to help every American feel the comfort and security of having health coverage. HealthSherpa is the largest and fastest-growing individual health coverage exchange in the United States, simplifying access to ACA and Medicare health plans from both federal and state marketplaces. Our secure, integrated technology platform empowers insurance agents, agencies, and carriers to quickly and accurately serve and support individuals as they select and use quality, affordable health plans.
The Enoch Pratt Free Library is one of the oldest free public library systems in the United States. We serve the residents of Baltimore with branches throughout the city, and the residents of Maryland as the State Library Resource Center. Our mission is to provide equal access to information and services that empower, enrich, and enhance the quality of life for all. http://www.prattlibrary.org/jobs
Bringing over 75 years of combined industry experience, Incline P&C Group is the premier insurance program market services firm. Privately owned and operated with an exclusive focus on the program insurance market, the executive teams experience and expertise combined with effective underwriting discipline and risk management provides each client with various platforms and associated services to meet almost any need in the industry.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.